2025 H2 -tulosraportti
165 päivää sitten
‧38 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 | ||
2023 H2 -tulosraportti 28.2.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·52 min sittenWhat a session! I've been peeking often today, but I think I'll stay veeeery still in the boat regarding Thor. I've started to think a bit about tomorrow, and I think there's a good chance we can get a "follow-through" and break the magical 6kr. And that after 6kr it actually takes off a bit for a while. It will be exciting regardless for the rest of the week. Personally, I had hoped to reach 6kr by Friday, the dreamer in me wants this to be at 15kr before the leaves fall. I don't believe in that scanarioet, but who knows…
Fully possible to break the 6-mark. But there probably needs to be more figures on the table before one can start to see the numbers you dream of.
·59 min sittenIf one looks at the 1-month chart, it looks like a double bottom pattern (W position) and it can be very positive. If one looks at the 1-year chart, it can look like a new cup and handle, which again will also be technically positive. If one then adds that it closed at the highest price ever, with a quite decent volume, then most things would indicate further upside. The only thing that could argue against it is that it could get a bull trap tomorrow where it starts like it started Monday last week, with an extremely sharp rise only to fall quite hard. Technically, it looks good, the volume is still high compared to what it was before the trend change, and indicates that investors are willing to pay a premium for this news that came. A fall back below 5 I would consider highly unlikely, which can also speak positively for further price change as the risk/reward is strengthened. 6,1 kr is a level that has previously been the next resistance level on previous uptrends, which has never been hit. Should we hit 6,1 and break it on high volume, then the "fear of heights" MAY disappear. If the fear of heights disappears, it often turns into euphoria. Euphoria can be both good and bad. Note that it MAY happen. Anything can happen, of course. This is not an investment recommendation, but my view on things.
·1 t sitten · MuokattuThor Medical. Norway's new industrial adventure. Something quiet, yet historical, is happening at Herøya in Porsgrunn. While most are still talking about oil, gas, and green energy, a small Norwegian company has just started commercial production of something that could prove to be far more valuable. Alpha emitters for next-generation cancer treatment. Thor Medical has done what few thought possible. They have built a factory that separates radioactive isotopes directly from natural thorium, without reactors, without cyclotrons, and with an environmental footprint that is radically better than traditional methods. AlphaOne, the company's first full-scale facility, is now operational. The first customer deliveries have already been sent. This is not just another biotech story. This is industry. For years, the availability of lead 212 and other alpha emitters has been a bottleneck for the rapidly growing radioligand therapy. Large pharmaceutical companies and biotech companies have queued up to get hold of the material that can deliver extremely precise radiation directly to cancer cells, with minimal damage to healthy tissue. Thor Medical solved the problem in a different way than most. Instead of relying on nuclear reactors, they use natural thorium as a raw material. The result is a more stable, scalable, and environmentally friendly production. With AlphaOne now in commercial operation, Norway is the only country in the world that can deliver this on an industrial scale without the use of reactors. Capacity starts modestly, but will be built up to around 21,000 patient doses annually after three years. Contracts have already been signed with both large pharmaceutical companies and smaller biotech companies. The demand is there. The supply has been lacking. Now it comes from Telemark. A classic Norwegian industrial adventure, just newer. There is something recognizable about this. Norway has done it before, taken natural resources, developed unique expertise, and built world-leading industry around it. Oil, aluminum, seafood, renewable energy. Now the same is happening in radiopharmaceuticals. The difference is that this time it's not about energy or materials in the traditional sense. It's about life. And about building a new type of export industry where the value per kilo is astronomical. While many companies are still dependent on others' production capacity, Thor Medical has control themselves. Own factory. Own technology. Own supply chain. It is precisely this type of structural advantage that has historically created the great Norwegian industrial adventures. It is still early. Volumes are small at the start, and it will take time before revenues truly show in the accounts. But the direction is clear. The factory is operational. Deliveries have started. Demand is increasing. If Thor Medical succeeds in scaling, and if the market for targeted alpha therapy grows as analysts expect, this could become something far more than a successful biotech company. It could be the start of a new Norwegian industrial cluster, with Herøya as one of the hubs. Norway has created energy adventures before. Now it's cancer treatment's turn. And this time, the adventure starts at Herøya.
·1 t sittenWhat if, on August 28th, we get an indication of high demand for Trmed's products, and that there will be a vote on an emission for an earlier construction start of alphatwo? The idea is based on the expansion of capacity that happened a short while ago at alphaone. And the demand.
CEO at Thor has verified and confirmed to Oslo Børs that they are self-financed until they have confirmed profit in Q3-Q4 next year. No share issue. Money is now pouring in.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 H2 -tulosraportti
165 päivää sitten
‧38 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·52 min sittenWhat a session! I've been peeking often today, but I think I'll stay veeeery still in the boat regarding Thor. I've started to think a bit about tomorrow, and I think there's a good chance we can get a "follow-through" and break the magical 6kr. And that after 6kr it actually takes off a bit for a while. It will be exciting regardless for the rest of the week. Personally, I had hoped to reach 6kr by Friday, the dreamer in me wants this to be at 15kr before the leaves fall. I don't believe in that scanarioet, but who knows…Fully possible to break the 6-mark. But there probably needs to be more figures on the table before one can start to see the numbers you dream of.
- ·59 min sittenIf one looks at the 1-month chart, it looks like a double bottom pattern (W position) and it can be very positive. If one looks at the 1-year chart, it can look like a new cup and handle, which again will also be technically positive. If one then adds that it closed at the highest price ever, with a quite decent volume, then most things would indicate further upside. The only thing that could argue against it is that it could get a bull trap tomorrow where it starts like it started Monday last week, with an extremely sharp rise only to fall quite hard. Technically, it looks good, the volume is still high compared to what it was before the trend change, and indicates that investors are willing to pay a premium for this news that came. A fall back below 5 I would consider highly unlikely, which can also speak positively for further price change as the risk/reward is strengthened. 6,1 kr is a level that has previously been the next resistance level on previous uptrends, which has never been hit. Should we hit 6,1 and break it on high volume, then the "fear of heights" MAY disappear. If the fear of heights disappears, it often turns into euphoria. Euphoria can be both good and bad. Note that it MAY happen. Anything can happen, of course. This is not an investment recommendation, but my view on things.
- ·1 t sitten · MuokattuThor Medical. Norway's new industrial adventure. Something quiet, yet historical, is happening at Herøya in Porsgrunn. While most are still talking about oil, gas, and green energy, a small Norwegian company has just started commercial production of something that could prove to be far more valuable. Alpha emitters for next-generation cancer treatment. Thor Medical has done what few thought possible. They have built a factory that separates radioactive isotopes directly from natural thorium, without reactors, without cyclotrons, and with an environmental footprint that is radically better than traditional methods. AlphaOne, the company's first full-scale facility, is now operational. The first customer deliveries have already been sent. This is not just another biotech story. This is industry. For years, the availability of lead 212 and other alpha emitters has been a bottleneck for the rapidly growing radioligand therapy. Large pharmaceutical companies and biotech companies have queued up to get hold of the material that can deliver extremely precise radiation directly to cancer cells, with minimal damage to healthy tissue. Thor Medical solved the problem in a different way than most. Instead of relying on nuclear reactors, they use natural thorium as a raw material. The result is a more stable, scalable, and environmentally friendly production. With AlphaOne now in commercial operation, Norway is the only country in the world that can deliver this on an industrial scale without the use of reactors. Capacity starts modestly, but will be built up to around 21,000 patient doses annually after three years. Contracts have already been signed with both large pharmaceutical companies and smaller biotech companies. The demand is there. The supply has been lacking. Now it comes from Telemark. A classic Norwegian industrial adventure, just newer. There is something recognizable about this. Norway has done it before, taken natural resources, developed unique expertise, and built world-leading industry around it. Oil, aluminum, seafood, renewable energy. Now the same is happening in radiopharmaceuticals. The difference is that this time it's not about energy or materials in the traditional sense. It's about life. And about building a new type of export industry where the value per kilo is astronomical. While many companies are still dependent on others' production capacity, Thor Medical has control themselves. Own factory. Own technology. Own supply chain. It is precisely this type of structural advantage that has historically created the great Norwegian industrial adventures. It is still early. Volumes are small at the start, and it will take time before revenues truly show in the accounts. But the direction is clear. The factory is operational. Deliveries have started. Demand is increasing. If Thor Medical succeeds in scaling, and if the market for targeted alpha therapy grows as analysts expect, this could become something far more than a successful biotech company. It could be the start of a new Norwegian industrial cluster, with Herøya as one of the hubs. Norway has created energy adventures before. Now it's cancer treatment's turn. And this time, the adventure starts at Herøya.
- ·1 t sittenWhat if, on August 28th, we get an indication of high demand for Trmed's products, and that there will be a vote on an emission for an earlier construction start of alphatwo? The idea is based on the expansion of capacity that happened a short while ago at alphaone. And the demand.CEO at Thor has verified and confirmed to Oslo Børs that they are self-financed until they have confirmed profit in Q3-Q4 next year. No share issue. Money is now pouring in.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 | ||
2023 H2 -tulosraportti 28.2.2024 |
2025 H2 -tulosraportti
165 päivää sitten
‧38 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 | ||
2023 H2 -tulosraportti 28.2.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·52 min sittenWhat a session! I've been peeking often today, but I think I'll stay veeeery still in the boat regarding Thor. I've started to think a bit about tomorrow, and I think there's a good chance we can get a "follow-through" and break the magical 6kr. And that after 6kr it actually takes off a bit for a while. It will be exciting regardless for the rest of the week. Personally, I had hoped to reach 6kr by Friday, the dreamer in me wants this to be at 15kr before the leaves fall. I don't believe in that scanarioet, but who knows…Fully possible to break the 6-mark. But there probably needs to be more figures on the table before one can start to see the numbers you dream of.
- ·59 min sittenIf one looks at the 1-month chart, it looks like a double bottom pattern (W position) and it can be very positive. If one looks at the 1-year chart, it can look like a new cup and handle, which again will also be technically positive. If one then adds that it closed at the highest price ever, with a quite decent volume, then most things would indicate further upside. The only thing that could argue against it is that it could get a bull trap tomorrow where it starts like it started Monday last week, with an extremely sharp rise only to fall quite hard. Technically, it looks good, the volume is still high compared to what it was before the trend change, and indicates that investors are willing to pay a premium for this news that came. A fall back below 5 I would consider highly unlikely, which can also speak positively for further price change as the risk/reward is strengthened. 6,1 kr is a level that has previously been the next resistance level on previous uptrends, which has never been hit. Should we hit 6,1 and break it on high volume, then the "fear of heights" MAY disappear. If the fear of heights disappears, it often turns into euphoria. Euphoria can be both good and bad. Note that it MAY happen. Anything can happen, of course. This is not an investment recommendation, but my view on things.
- ·1 t sitten · MuokattuThor Medical. Norway's new industrial adventure. Something quiet, yet historical, is happening at Herøya in Porsgrunn. While most are still talking about oil, gas, and green energy, a small Norwegian company has just started commercial production of something that could prove to be far more valuable. Alpha emitters for next-generation cancer treatment. Thor Medical has done what few thought possible. They have built a factory that separates radioactive isotopes directly from natural thorium, without reactors, without cyclotrons, and with an environmental footprint that is radically better than traditional methods. AlphaOne, the company's first full-scale facility, is now operational. The first customer deliveries have already been sent. This is not just another biotech story. This is industry. For years, the availability of lead 212 and other alpha emitters has been a bottleneck for the rapidly growing radioligand therapy. Large pharmaceutical companies and biotech companies have queued up to get hold of the material that can deliver extremely precise radiation directly to cancer cells, with minimal damage to healthy tissue. Thor Medical solved the problem in a different way than most. Instead of relying on nuclear reactors, they use natural thorium as a raw material. The result is a more stable, scalable, and environmentally friendly production. With AlphaOne now in commercial operation, Norway is the only country in the world that can deliver this on an industrial scale without the use of reactors. Capacity starts modestly, but will be built up to around 21,000 patient doses annually after three years. Contracts have already been signed with both large pharmaceutical companies and smaller biotech companies. The demand is there. The supply has been lacking. Now it comes from Telemark. A classic Norwegian industrial adventure, just newer. There is something recognizable about this. Norway has done it before, taken natural resources, developed unique expertise, and built world-leading industry around it. Oil, aluminum, seafood, renewable energy. Now the same is happening in radiopharmaceuticals. The difference is that this time it's not about energy or materials in the traditional sense. It's about life. And about building a new type of export industry where the value per kilo is astronomical. While many companies are still dependent on others' production capacity, Thor Medical has control themselves. Own factory. Own technology. Own supply chain. It is precisely this type of structural advantage that has historically created the great Norwegian industrial adventures. It is still early. Volumes are small at the start, and it will take time before revenues truly show in the accounts. But the direction is clear. The factory is operational. Deliveries have started. Demand is increasing. If Thor Medical succeeds in scaling, and if the market for targeted alpha therapy grows as analysts expect, this could become something far more than a successful biotech company. It could be the start of a new Norwegian industrial cluster, with Herøya as one of the hubs. Norway has created energy adventures before. Now it's cancer treatment's turn. And this time, the adventure starts at Herøya.
- ·1 t sittenWhat if, on August 28th, we get an indication of high demand for Trmed's products, and that there will be a vote on an emission for an earlier construction start of alphatwo? The idea is based on the expansion of capacity that happened a short while ago at alphaone. And the demand.CEO at Thor has verified and confirmed to Oslo Børs that they are self-financed until they have confirmed profit in Q3-Q4 next year. No share issue. Money is now pouring in.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt